This analysis ultimately identified a gene containing the WW-domain containing oxidoreductase (WWOX) domain as a drug target for TSN’s anti-tumor effects, a finding that was further validated in subsequent experiments (Yang et al., 2021). This evidence concerns the gene WWOX and neoplasm.